We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arcontech Group Plc | LSE:ARC | London | Ordinary Share | GB00BDBBJZ03 | ORD GBP0.125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.50 | -1.41% | 105.00 | 102.00 | 108.00 | 106.50 | 105.00 | 106.50 | 21,162 | 11:34:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Computer Programming Service | 2.73M | 980k | 0.0733 | 14.32 | 14.04M |
TIDMARC
RNS Number : 0198S
Arcontech Group PLC
27 September 2017
AorTech International plc
("AorTech"or the "Company")
Result of AGM
AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, is pleased to announce that at the Annual General Meeting held today, all the resolutions were duly passed.
For further information contact:
AorTech International plc
Eddie McDaid, Chief Executive Tel: +44 (0)7802 920869
AorTech International plc
Bill Brown, Chairman Tel: +44 (0)7730 718296
finnCap Limited
Jonny Franklin-Adams / Giles Rolls Tel: +44 20 7220 0500
About AorTech:
AorTech has developed biostable, implantable polymers, including Elast-Eon(TM) and ECSil(TM) the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.
Elast-Eon(TM) and ECSil(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGOKODBABKDBCB
(END) Dow Jones Newswires
September 27, 2017 12:23 ET (16:23 GMT)
1 Year Arcontech Chart |
1 Month Arcontech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions